Search | Clinical Trials Finder

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 15
States / cities: New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more

Conditions: Glaucoma
Interventions: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005%, placebo; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 2
States / cities: Lakeland, Florida • Bourbonnais, Illinois

Conditions: Glaucoma
Interventions: Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemangioma
Interventions: timolol maleate 0.5% gel; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 7 Days to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Xalacom, Xalatan, Timolol; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 64
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Wound Healing, Mohs Micrographic Surgery
Interventions: Timolol Maleate Solution, Standard of Care; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions: PhXA41, timolol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Surgical Wounds, Mohs Surgery
Interventions: Topical Timolol, Normal Saline; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 28
States / cities: Chandler, Arizona • Duarte, California • Fullerton, California + 25 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions: Latanoprost with Pilocarpine vs Timolol or Cosopt; Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 50 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma Open-angle
Interventions: Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: QLS-101, Timolol Maleate; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albany, Georgia

Conditions: Glaucoma
Interventions: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Glendale, California • Newport Beach, California • Pasadena, California + 11 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Infantile Hemangiomas
Interventions: Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 8 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mohs Micrographic Surgery, Excision Margin
Interventions: Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Sacramento, California

Search by objective public record fields.

AR-12286 in Combination With Latanoprost

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Cosopt Versus Xalatan

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

The International Collaborative Exfoliation Syndrome Treatment Study

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Adjunctive Study of AL-37807 Ophthalmic Suspension

Dose-Ranging Study of the Bimatoprost Ocular Insert

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing